Opinion
Video
Panelists discuss their overall perceptions of oral selective estrogen receptor degraders (SERDs) and their impact on the treatment landscape and share their experiences with elacestrant in clinical practice.
Video content above is prompted by the following:
Dr. Bardia to All Panelists: